Virtual Library

Start Your Search

Jiang Zhu



Author of

  • +

    P86 - Targeted Therapy - Clinically Focused - New Target (ID 263)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P86.13 - Anlotinib is Active for the Patients Failed from the Prior Bevacizumab Treatment: Anti-Angiogenic Therapy might be Cross-Line Used (ID 1568)

      00:00 - 00:00  |  Presenting Author(s): Jiang Zhu

      • Abstract
      • Slides

      Introduction

      Both bevacizumab and anlotinib have the anti-angiogenic ability, the purpose of this study was to initially observe the short-term efficacy of anlotinib after the failure with bevacizumab treatment in advanced non-small cell lung cancer.

      Methods

      We retrospectively collected the clinical data of anlotinib in the patients with NSCLC who were treating with anlotinib after the failure of prior bevacizumab in West China Hospital Cancer Center. Therapeutic efficacy evaluation was performed on the Picture Archiving and Communication Systems according to Response Evaluation Criteria In Solid Tumour 1.1, and the optimal response and progression-free survival of anlotinib were calculated with reference to imaging reports and clinical practice and the preliminary analysis of factors that affect the outcome of anlotinib was performed.

      Results

      From April 2017 to October 2019, twenty-four advanced NSCLC patients who had been previously treated with bevacizumab were administered anlotinib. One patient was lost to follow-up, two were discontinued anlotinib therapy due to hematemesis and severe fatigue, twenty-one patients were performed the tumor evaluation. The best responses were: partial response (n = 3); stable disease (n = 14); and progression disease (n = 4). The objective response rate was 14.3%, the disease control rate was 81.0%. A total of 15 patients had measurable lesions, the changes in measurable lesions from baseline are shown in Figure 1. The median progression-free survival of anlotinib treatment was 4.0 months (95% CI 1.8-6.2 months) (Figure 2). Univariate analysis did not find the influencing factors affecting the progression-free survival of anlotinib.

      fig 1.jpgfig 2.jpg

      Conclusion

      Anlotinib is effective for the patients with advanced NSCLC who had failed the prior bevacizumab therapy. The further large sample size study is warranted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.